Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6745521 | 1.00 | CYP4F2 (0.37) | CYP4F2CYP4A11MGLLALDH1A1GAA | |
| SCHEMBL6744520 | 0.92 | CYP4F2 (0.36) | CYP4F2CYP4A11MGLLALDH1A1GAA | |
| SCHEMBL6744908 | 0.92 | CYP4F2 (0.37) | CYP4F2CYP4A11MGLLALDH1A1GAA | |
| SCHEMBL6745299 | 0.89 | CYP4F2 (0.38) | CYP4F2CYP4A11MGLLALDH1A1GAA | |
| SCHEMBL6799092 | 0.89 | CYP4F2 (0.38) | CYP4F2CYP4A11MGLLALDH1A1GAA | |
| SCHEMBL10134601 | 0.88 | CYP4F2 (0.37) | CYP4F2CYP4A11MGLLALDH1A1GAA | |
| SCHEMBL13265178 | 0.84 | CYP4F2 (0.36) | CYP4F2CYP4A11MGLLALDH1A1GAA | |
| SCHEMBL6745211 | 0.84 | CYP4F2 (0.36) | CYP4F2CYP4A11MGLLALDH1A1GAA | |
| SCHEMBL10134599 | 0.83 | CYP4F2 (0.38) | CYP4F2CYP4A11MGLLALDH1A1GAA | |
| SCHEMBL6745216 | 0.83 | CYP4F2 (0.36) | CYP4F2CYP4A11MGLLALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20110319359-A1 | INDANYL COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319359-A1 | INDANYL COMPOUNDS | RYR2, ORAI1, CASR | CYP4F2 868/4885CYP4A11 403/4885MGLL 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.